Synopsis: In a recently issued final written decision, the Patent Trial and Appeal Board (the “Board”) found all challenged claims of U.S.

These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses ...

These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses ...

(Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.

(Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen ...

The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. Receive News & Ratings for ...